Beautyeurope.eu is a company that sells medical devices, provides knowledge concerningregenerative and aesthetic medicine, develops innovative products and takes care of the progresstheir clients make in thefields where they want to strive for perfection.The company aims at supplying the market with certified, high-quality medical products.
9.09.2022
Dr Bartłomiej Sobolewski
13:00-13:30
Dr Bartłomiej Sobolewski
he eye area - daily challenges. Choosing the optimal technologies and how to apply them.
I will talk about dedicated treatments for the difficult eye area. How to deal with different problems and choose the right therapy.
dr Magdalena Trzcińska – Kubik
13:30-14:00
dr Magdalena Trzcińska–Kubik
The natural concept of beauty - does more means better??
One of my special interests is regenerative medicine – the use of platelet rich plasma and fibrin, which I successfully use in both surgical and aesthetic medicine procedures (skin regeneration, as well as the treatment of scars and stretch marks). I will talk about natural regeneration methods combining dentistry and aesthetic medicine.
10.09.2022
Lek. med. Magdalena Kędzia
12:30–13:30
Dr Magdalena Kędzia
Autologous techniques - hit or miss?
Autologous techniques are the simplest tissue transplant. I will talk about its use and possibilities in aesthetic medicine, treatment of scars and scarring, alopecia and psoriasis and we will consider whether autologous means safe
Dr Bartłomiej Sobolewski
13:00-13:30
Dr Bartłomiej Sobolewski
Lenisna & Juvelook - the effectiveness and safety of polylactic acid in Anti-Aging therapy
Lenisna and Juvelook are one of the strongest and most durable tissue stimulants on the world market.
The unique biostimulating properties of PDLLA, confirmed by clinical studies, distinguish these products from other available polylactic acid preparations. This properties are the basis of a unique therapy that gives spectacular and long-term results, both on the face, including the eye area, and on the body.
The constant structure of microparticles affects the safety of therapies with their use:
their round, porous, mesh-structured shape, uniform size from 50 to 60 µm for the Lenisna and 10 to 40 µm for the Juvelook and a formulation without CMC (carboxymethylcellulose), replaced by uncrosslinked hyaluronic acid.